The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: Systematic evaluation and suggestion for improvement

Journal of Postgraduate Medicine

Volumn 54, Issue 3, 2008, Pages 186-190

  Chen, C ^a   Chen, L ^b   Yang, G ^a   Li, Y ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Central Hospital of Xian'ning City   (China)

Author keywords

Clinical staging; Colorectal cancer; Early diagnosis; Protein biochip tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHIP; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER STAGING; CHI SQUARE TEST; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AREA UNDER CURVE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 47549088298     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.40963     Document Type: Article

References (22)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Dong ZW, Qiao YL, Li LD, Chen YD, Wang RT, Lei TH, et al. Report of Chinese cancer control strategy. China Cancer 2002;11:250-60.
3. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
4. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology, Part I: molecular basis, Part II: clinical uses. Cancer Treat Rev 2007;33:230-83.
5. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-60.
6. Sun ZH, Fu XL, Zhang L, Yang X, Liu F, Hu G. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res 2004;24:1159-66.
7. Yu DY. Application of multi-tumor markers protein chip assistance diagnostic system for detection of various tumors. China Trop Med 2005;5:414-16.
8. Liang Z, Wang HF, Wu AZ, Fu SM. Clinical value of 12 tumor markers protein biochip detection of digestive system neoplasm. China Trop Med 2005;5:407-09.
9. Jiang ZJ, Zhou W X, Lin W, Huang QX. Application of multi-tumor markers protein chip diagnose system in the diagnosing of intestinal neoplasms. J Mod Lab Med 2005;20:17-19.
10. Mou JH, Li ZP, Wang D, Ma Y, Xiao HL, Zhang QH. Combined detection of multiple tumor marker and its diagnostic value in colorectal cancer. J Digest Surg 2005;4:268-70.
11. Zhong ZY, Wang D, Li ZP, Li MX, Dai N, Cao XJ, et al. Clinical significance of C-12 multiple tumor marker protein chip detective system in diagnosing colorectal carcinoma. Chongqing Med 2007;36:2406-08.
12. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
13. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935-53.
14. Bitarte N, Bandres E, Zarate R, Ramirez N, Garcia-Foncillas J. Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 2007;13:5813-21.
15. Madoz-Gurpide J, Lopez-Serra P, Martinez-Torrecuadrada JL, Sanchez L, Lombardia L, Casal JI. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 2006;5:1471-83.
16. Cowan ML, Vera J. Proteomics: advances in biomarker discovery. Expert Rev Proteomics 2008;5:21-23.
17. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004;66:296-302.
18. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Kedra B, Konopko M, Szmitkowski M. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta 2006;371:143-47.
19. Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, et al. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum 2006;49:883-94.
20. Abdel-Aziz MM, Lotfy M, El-Kady IM, Abozaid M. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev 2006;Epub ahead of print.
21. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.
22. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208-12.